Biomaneo is accelerating its development by acquiring stakes in two local institutional investors

The first kit developed by Biomaneo (NeoSickle) for the newborn sickle cell disease screening is now ready to be marketed. The financial entry into the capital of two investors, INVEST PME and BDR IT, with the support of other local financial partners such as BPI France, will help Biomaeo to launch its international business. This first step will contribute to accelerate the research and development program in order for Biomaneo to propose rapidly new screening kits on the market.